120 related articles for article (PubMed ID: 15549730)
1. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
[TBL] [Abstract][Full Text] [Related]
2. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
[TBL] [Abstract][Full Text] [Related]
3. The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization.
Partidos CD; Hoebeke J; Moreau E; Chaloin O; Tunis M; Belliard G; Briand JP; Desgranges C; Muller S
Eur J Immunol; 2005 May; 35(5):1521-9. PubMed ID: 15789358
[TBL] [Abstract][Full Text] [Related]
4. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
[TBL] [Abstract][Full Text] [Related]
5. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
7. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
[TBL] [Abstract][Full Text] [Related]
8. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
9. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
10. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
[TBL] [Abstract][Full Text] [Related]
11. Full-length HIV-1 Tat protein necessary for a vaccine.
Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
[TBL] [Abstract][Full Text] [Related]
12. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach.
Karasev AV; Foulke S; Wellens C; Rich A; Shon KJ; Zwierzynski I; Hone D; Koprowski H; Reitz M
Vaccine; 2005 Mar; 23(15):1875-80. PubMed ID: 15734059
[TBL] [Abstract][Full Text] [Related]
13. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
14. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
Re MC; Gibellini D; Vitone F; La Placa M
New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
[TBL] [Abstract][Full Text] [Related]
15. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
[TBL] [Abstract][Full Text] [Related]
16. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma.
Demirhan I; Chandra A; Mueller F; Mueller H; Biberfeld P; Hasselmayer O; Chandra P
J Hum Virol; 2000; 3(3):137-43. PubMed ID: 10881993
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
[TBL] [Abstract][Full Text] [Related]
20. Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses.
Ramakrishna L; Anand KK; Mahalingam M; Mohankumar KM; Ramani S; Siddappa NB; Ranga U
Vaccine; 2004 Jun; 22(20):2586-98. PubMed ID: 15193384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
